Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7771950 · 1 trial · 1 indication
Time from randomization to disease progression or death, according to standard criteria (Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)).
| Arm | Type | Description |
|---|---|---|
| Arm A - RO7771950 Dose Type 1 | EXPERIMENTAL | - |
| Arm B - RO7771950 Dose Type 2 | EXPERIMENTAL | - |
| Arm C - Tucatinib | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| RO7771950 | DRUG | Participants will receive one of two doses of RO7771950 orally (PO) twice a day (BID). |
| Tucatinib | DRUG | Participants will receive a dose of tucatinib PO BID. |
| Trastuzumab | DRUG | Participants will receive trastuzumab in accordance with local prescribing information, either through intravenous (IV) or subcutaneously (SC). |
| Capecitabine | DRUG | Participants will receive capecitabine according to local prescribing information. Capecitabine will be administered PO BID. |
Inclusion Criteria: * Pathologically documented locally advanced inoperable (LAI) or metastatic breast cancer (MBC) with confirmed HER2-positive status by central laboratory. * Measurable disease as per by RECIST v1.1 in stage 1. Non-measurable disease allowed in stage 2. * Previously treated (stab...
RO7771950 is an investigational small molecule being studied for the treatment of HER2-positive breast cancer. It is currently in Phase 2 clinical development for people with locally advanced or metastatic HER2-positive breast cancer. The drug is being evaluated in combination with trastuzumab and capecitabine.
RO7771950 is a small molecule being developed for HER2-positive breast cancer. The specific molecular target of RO7771950 has not been disclosed. It is being studied in combination with trastuzumab and capecitabine for the treatment of locally advanced or metastatic HER2-positive breast cancer.
RO7771950 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is currently conducting a Phase 2 clinical trial of RO7771950 for HER2-positive breast cancer.
RO7771950 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of HER2-positive breast cancer.
RO7771950 is being studied in one active Phase 2 clinical trial, NCT07413939. This trial compares RO7771950 versus tucatinib in combination with trastuzumab and capecitabine in people with locally advanced or metastatic HER2-positive breast cancer. The trial is recruiting participants across multiple countries.
No, RO7771950 is not the same as tucatinib. RO7771950 is an investigational drug being compared against tucatinib in a clinical trial. The trial, NCT07413939, evaluates RO7771950 versus tucatinib, both in combination with trastuzumab and capecitabine, for HER2-positive breast cancer.